Oncogenic MYC amplifies mitotic perturbations.
MYC
SAE2
chromosome instability
mitosis
Journal
Open biology
ISSN: 2046-2441
Titre abrégé: Open Biol
Pays: England
ID NLM: 101580419
Informations de publication
Date de publication:
30 08 2019
30 08 2019
Historique:
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
1
5
2020
Statut:
ppublish
Résumé
The oncogenic transcription factor MYC modulates vast arrays of genes, thereby influencing numerous biological pathways including biogenesis, metabolism, proliferation, apoptosis and pluripotency. When deregulated, MYC drives genomic instability via several mechanisms including aberrant proliferation, replication stress and ROS production. Deregulated MYC also promotes chromosome instability, but less is known about how MYC influences mitosis. Here, we show that deregulating MYC modulates multiple aspects of mitotic chromosome segregation. Cells overexpressing MYC have altered spindle morphology, take longer to align their chromosomes at metaphase and enter anaphase sooner. When challenged with a variety of anti-mitotic drugs, cells overexpressing MYC display more anomalies, the net effect of which is increased micronuclei, a hallmark of chromosome instability. Proteomic analysis showed that MYC modulates multiple networks predicted to influence mitosis, with the mitotic kinase PLK1 identified as a central hub. In turn, we show that MYC modulates several PLK1-dependent processes, namely mitotic entry, spindle assembly and SAC satisfaction. These observations thus underpin the pervasive nature of oncogenic MYC and provide a mechanistic rationale for MYC's ability to drive chromosome instability.
Identifiants
pubmed: 31455158
doi: 10.1098/rsob.190136
pmc: PMC6731591
doi:
Substances chimiques
Proto-Oncogene Proteins c-myc
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
190136Subventions
Organisme : Medical Research Council
ID : MR/M008959/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1422/A19842
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C5759/A25254
Pays : United Kingdom
Références
Nat Med. 2016 Jul;22(7):744-53
pubmed: 27213815
Front Oncol. 2015 Jun 10;5:132
pubmed: 26114094
Nat Rev Mol Cell Biol. 2014 Jul;15(7):433-52
pubmed: 24954208
Oncogene. 2015 Sep 10;34(37):4799-807
pubmed: 25619835
J Cell Biol. 2010 Jul 12;190(1):25-34
pubmed: 20624899
Nucleic Acids Res. 1995 May 25;23(10):1686-90
pubmed: 7784172
Dev Cell. 2007 Oct;13(4):566-79
pubmed: 17925231
Cold Spring Harb Perspect Med. 2014 Apr 01;4(4):a014373
pubmed: 24692190
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11
pubmed: 17360485
Curr Biol. 2018 Nov 5;28(21):3422-3429.e5
pubmed: 30415700
Cancer Cell. 2009 Jan 6;15(1):67-78
pubmed: 19111882
Science. 1999 Oct 29;286(5441):971-4
pubmed: 10542155
Curr Biol. 2004 Apr 6;14(7):611-7
pubmed: 15062103
Cell Cycle. 2007 Feb 1;6(3):339-52
pubmed: 17297307
Cold Spring Harb Perspect Med. 2014 Jun 17;4(9):a014399
pubmed: 24939054
Br J Cancer. 2003 Oct 20;89(8):1479-85
pubmed: 14562020
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Cell. 2013 Jul 8;24(1):75-89
pubmed: 23792191
Blood. 2010 Sep 2;116(9):1498-505
pubmed: 20519624
Cold Spring Harb Perspect Med. 2014 Feb 01;4(2):
pubmed: 24492846
Cancer Cell. 2015 Jul 13;28(1):129-40
pubmed: 26175417
Biochem Soc Trans. 2017 Jun 15;45(3):709-717
pubmed: 28620032
Nat Chem Biol. 2017 Nov;13(11):1164-1171
pubmed: 28892090
Cell. 2018 Sep 6;174(6):1347-1360
pubmed: 30193109
Nat Rev Drug Discov. 2010 Aug;9(8):643-60
pubmed: 20671765
Sci Rep. 2016 Jul 14;6:29741
pubmed: 27412232
Curr Biol. 2018 Sep 10;28(17):R929-R930
pubmed: 30205061
Biochimie. 2006 Nov;88(11):1515-31
pubmed: 16919864
J Cell Biol. 2003 Apr 28;161(2):267-80
pubmed: 12719470
Nature. 1997 May 22;387(6631):422-6
pubmed: 9163430
Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5839-44
pubmed: 20167803
Hepatology. 2008 Oct;48(4):1302-11
pubmed: 18798339
Cold Spring Harb Perspect Med. 2014 Jan 01;4(1):a014357
pubmed: 24384812
Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803
pubmed: 23175282
Oncotarget. 2015 Nov 3;6(34):36472-88
pubmed: 26472023
Mol Cell Biol. 1999 Aug;19(8):5339-51
pubmed: 10409725
Cell. 2002 May 3;109(3):321-34
pubmed: 12015982
Nat Rev Clin Oncol. 2018 Mar;15(3):139-150
pubmed: 29297505
Nat Rev Cancer. 2004 Dec;4(12):927-36
pubmed: 15573114
EMBO J. 1996 Dec 2;15(23):6595-604
pubmed: 8978686
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890832
Nat Med. 2007 Jul;13(7):820-7
pubmed: 17589519
Cell Rep. 2017 Dec 19;21(12):3483-3497
pubmed: 29262328
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13836-41
pubmed: 20643922
Mol Cell. 2016 Nov 3;64(3):493-506
pubmed: 27773673
EMBO J. 2019 Apr 1;38(7):
pubmed: 30782962
Cancer Cell. 2014 Sep 8;26(3):414-427
pubmed: 25175806
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3534-9
pubmed: 20133585
Cold Spring Harb Perspect Med. 2013 Aug 01;3(8):
pubmed: 23906881
Oncogene. 2017 Aug 24;36(34):4819-4827
pubmed: 28436952
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890833
Nat Commun. 2014 Aug 18;5:4632
pubmed: 25130259
Cell Cycle. 2007 May 2;6(9):1024-9
pubmed: 17426456
Dev Cell. 2004 Jul;7(1):45-60
pubmed: 15239953
Cold Spring Harb Perspect Med. 2014 Jan 01;4(1):a020990
pubmed: 24384817
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9
pubmed: 11983916
J Clin Invest. 2018 Dec 3;128(12):5517-5530
pubmed: 30260324
Curr Biol. 2007 Feb 20;17(4):316-22
pubmed: 17291758
Cancer Res. 2002 Jun 15;62(12):3507-10
pubmed: 12067996
Science. 2012 Jan 20;335(6066):348-53
pubmed: 22157079
Nat Rev Cancer. 2010 Dec;10(12):825-41
pubmed: 21102634